Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quinapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 16/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinapril SCHEMBL13575806 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL29380303 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL29846170 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL678447 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL11286555 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL11294979 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL19361887 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL994608 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL9094436 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 | |
| Quinapril SCHEMBL11286551 | 1.00 | ACE (1.00) | ACEABCB11PDE3ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 34108 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260083968-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS (TTFIELDS) AND ACE INHIBITORS | NOVOCURE GMBH (CH) | 2026-03-26 | — | — | US | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| EP-4684832-A2 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | Vifor (International) Ltd. (CH) | 2026-01-28 | — | — | EP | claimed |
| US-4793998-A | ASCORBIC ACID AS STABILIZER FOR ANGIOTENSIN CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1988-12-27 | — | — | US | claimed |
| EP-0285992-A1 | Crystalline quinapril and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1988-10-12 | — | — | EP | claimed |
| EP-0280999-A2 | Stabilized pharmaceutical compositions containing angiotensin-converting enzyme inhibitors | WARNER-LAMBERT COMPANY (US) | 1988-09-07 | — | — | EP | claimed |
| EP-0135182-B1 | PROCESS FOR THE PRODUCTION OF N-ALKYLATED DIPEPTIDES AND OF THEIR ESTERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-07-27 | — | — | EP | claimed |
| US-4743450-A | ANGIOTENSION CONVERTING ENZYME INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-05-10 | — | — | US | claimed |
| EP-0265685-A2 | Combination of ACE inhibitors with calcium antagonists, and their use in medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-05-04 | — | — | EP | claimed |
| EP-0264887-A1 | Drug compositions stabilized against oxidation and discoloration | WARNER-LAMBERT COMPANY (US) | 1988-04-27 | — | — | EP | claimed |
| EP-0264888-A1 | Stabilized drug compositions | WARNER-LAMBERT COMPANY (US) | 1988-04-27 | — | — | EP | claimed |
| EP-0220107-A2 | Use of angiotensin-converting enzyme inhibitors in macular degeneration | MERCK & CO. INC. (US) | 1987-04-29 | — | — | EP | claimed |
| US-4656188-A | Ace inhibitors in macular degeneration | MERCK & CO., INC. (US) | 1987-04-07 | — | — | US | claimed |